A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Imugene Limited
Sumitomo Pharma America, Inc.
National Institutes of Health Clinical Center (CC)
University of Chicago
Lund University Hospital
Epidemiological and Clinical Research Information Network
National Cancer Institute (NCI)
Tehran University of Medical Sciences
University Hospital Tuebingen